311 related articles for article (PubMed ID: 32416692)
21. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
22. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
Susanti NMP; Tjahjono DH
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361615
[TBL] [Abstract][Full Text] [Related]
23. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
Malínková V; Vylíčil J; Kryštof V
Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
[TBL] [Abstract][Full Text] [Related]
24. Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology.
Di Sante G; Pagé J; Jiao X; Nawab O; Cristofanilli M; Skordalakes E; Pestell RG
Expert Rev Anticancer Ther; 2019 Jul; 19(7):569-587. PubMed ID: 31219365
[No Abstract] [Full Text] [Related]
25. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
[TBL] [Abstract][Full Text] [Related]
26. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
Grant S; Roberts JD
Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in CDK inhibitors for cancer therapy.
Heptinstall AB; Adiyasa I; Cano C; Hardcastle IR
Future Med Chem; 2018 Jun; 10(11):1369-1388. PubMed ID: 29846081
[TBL] [Abstract][Full Text] [Related]
28. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
29. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
McInnes C
Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
[TBL] [Abstract][Full Text] [Related]
30. Cyclin-dependent kinase modulators and cancer therapy.
Gallorini M; Cataldi A; di Giacomo V
BioDrugs; 2012 Dec; 26(6):377-91. PubMed ID: 22928661
[TBL] [Abstract][Full Text] [Related]
31. Targeting cyclin-dependent kinases in anti-neoplastic therapy.
Bruyère C; Meijer L
Curr Opin Cell Biol; 2013 Dec; 25(6):772-9. PubMed ID: 24011867
[TBL] [Abstract][Full Text] [Related]
32. Recent advances on CDK inhibitors: An insight by means of in silico methods.
Tutone M; Almerico AM
Eur J Med Chem; 2017 Dec; 142():300-315. PubMed ID: 28802482
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
DePinto W; Chu XJ; Yin X; Smith M; Packman K; Goelzer P; Lovey A; Chen Y; Qian H; Hamid R; Xiang Q; Tovar C; Blain R; Nevins T; Higgins B; Luistro L; Kolinsky K; Felix B; Hussain S; Heimbrook D
Mol Cancer Ther; 2006 Nov; 5(11):2644-58. PubMed ID: 17121911
[TBL] [Abstract][Full Text] [Related]
34. Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
Xie Z; Hou S; Yang X; Duan Y; Han J; Wang Q; Liao C
J Med Chem; 2022 May; 65(9):6356-6389. PubMed ID: 35235745
[TBL] [Abstract][Full Text] [Related]
35. Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.
Cheng W; Yang Z; Wang S; Li Y; Wei H; Tian X; Kan Q
Eur J Med Chem; 2019 Feb; 164():615-639. PubMed ID: 30639897
[TBL] [Abstract][Full Text] [Related]
36. Cyclin dependent kinases in cancer: potential for therapeutic intervention.
Canavese M; Santo L; Raje N
Cancer Biol Ther; 2012 May; 13(7):451-7. PubMed ID: 22361734
[TBL] [Abstract][Full Text] [Related]
37. Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells.
Cho SJ; Kim YJ; Surh YJ; Kim BM; Lee SK
J Biol Chem; 2011 Jun; 286(22):19662-71. PubMed ID: 21478145
[TBL] [Abstract][Full Text] [Related]
38. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
Klein MA
Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
[TBL] [Abstract][Full Text] [Related]
39. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
[TBL] [Abstract][Full Text] [Related]
40. A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism.
Corsino P; Horenstein N; Ostrov D; Rowe T; Law M; Barrett A; Aslanidi G; Cress WD; Law B
J Biol Chem; 2009 Oct; 284(43):29945-55. PubMed ID: 19710018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]